7.6305.69% ( -0.460 )
Closed: Nov 12, 16:00:00 (EDT)Valuation
Current ValuationThe current P/E ratio is -16.01, below the reasonable range, cheaper than 97.54% of the time in the past 5 years, and the industry ranks 486/606, the industry Median -1.70.
-16.01xP/E
$7.63Stock price
$-0.48Earnings per share
-16.01xP/E
Stock price$7.63Earnings per share$-0.48
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -4.38x
- Typical range
- -6.97x–-2.60x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
013263952
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GILDUSGilead Sciences | -53.94x | 162.77% | $208.31B |
MRNAUSModerna | -33.12x | 1.52% | $92.36B |
CSLLYUSCSL Limited | -25.75x | -- | $66.42B |
NTRAUSNatera | -284.30x | 0.99% | $46.83B |
RVMDUSRevolution Medicines | -20.21x | 40.80% | $37.80B |
ROIVUSRoivant Sciences | -84.14x | 67.79% | $28.98B |
INSMUSInsmed | -42.77x | 74.47% | $25.90B |
BNTXUSBioNTech SE | -12.46x | 29.49% | $21.08B |
ASNDUSAscendis Pharmac | -- | 465.68% | $17.57B |
BBIOUSBridgebio Pharma | -25.72x | 30.83% | $15.23B |
SMMTUSSummit Therapeutics | -14.44x | 23.12% | $12.03B |
BMRNUSBioMarin Pharma | -574.55x | 56.09% | $10.98B |
KYMRUSKymera Therapeutics | -30.26x | 8.74% | $10.57B |
PCVXUSVaxcyte | -8.92x | 42.58% | $10.24B |
MDGLUSMadrigal Pharma | -63.54x | 86.93% | $9.88B |
SYREUSSpyre Therapeutics | -43.63x | 59.92% | $9.77B |
PRAXUSPraxis Precision Medicines | -25.23x | 0.60% | $9.07B |
ALKSUSAlkermes | -22,491.98x | 134.90% | $7.89B |
CYTKUSCytokinetics | -10.06x | 8.60% | $7.82B |
RYTMUSRhythm Pharma | -38.41x | 51.65% | $7.62B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
